Aerosolized terbutaline sulfate in the treatment of bronchospasm

Terbutaline sulfate, a relatively selective beta2 agonist, is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease. Studies have shown that when administered via an aerosol, terbutaline has a rapid onset, a prolonged duration of action, and a low incidence of systemic side effects. Because the drug is delivered directly to the bronchi, one can administer low doses of aerosolized terbutaline and achieve a bronchodilatory effect comparable to that achieved with higher doses of the oral form.